Citi Research issued a research report opening a downside 30-day catalyst watch on CHINA LIFE (02628.HK) -0.380 (-1.664%) Short selling $388.20M; Ratio 31.797% , and expressing concerns that the Company's 1H25 earnings growth may fall short of expectations, primarily due to declining interest rates, which could dent insurance service fees and net investment income, slower than the market's general expectation of a 20% YoY increase.The broker currently forecasted that CHINA LIFE's 1H25 net profit will grow by 5% YoY to RMB40.3 billion, a significant slowdown from 1Q25. Therefore, Citi Research kept rating at Buy on CHINA LIFE, with a target price of $26.1, as it remained optimistic about its brand advantage and long-term growth potential.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-08-08 16:25.)Related NewsHSBC Research: Lower Benchmark PIR for General Insurance Products Benefits CN Insurers; TPs for All Covered Insurers Raised